ArticleCancer immunology, immunotherapy : CII2008
CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged.
Article in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Effects of aging on anticancer therapy in murine cancer models.Cancer metastasis reviews · 2025Review
- Aging and immunity: the age-old tango.Genes & development · 2025Review
- Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy.Frontiers in endocrinology · 2023Article
- A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory ActivityFrontiers in pharmacology · 2020Article
- Modulating Immune Response with Nucleic Acid Nanoparticles.Molecules (Basel, Switzerland) · 2019Review
- Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention.Frontiers in immunology · 2019Review
- The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy.Frontiers in medicine · 2018Article
- The twilight of immunity: emerging concepts in aging of the immune system.Nature immunology · 2018Review
- In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.Molecular oncology · 2015Review
- A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly.Immune network · 2015Review
- Optimization of immunotherapy in elderly cancer patients.Critical reviews in oncogenesis · 2013Review
- Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.International immunopharmacology · 2012Article
- Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses.Cancer immunology, immunotherapy : CII · 2011Article
- Immunity, cancer and aging: lessons from mouse models.Aging and disease · 2011Article
- Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth.The Journal of experimental medicine · 2011Article
- Dysregulation of human Toll-like receptor function in aging.Ageing research reviews · 2011Review
- Article
- The effect of aging on OX40 agonist-mediated cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2009Review
- Cancer, aging and immunotherapy: lessons learned from animal models.Cancer immunology, immunotherapy : CII · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
aimThere is accumulative evidence indicating that targeting antigen presenting cells (APCs) with different types of adjuvants could result in the induction of antitumor immune responses. It has been hypothesized that APCs function may be altered in the elderly contributing to a decline in the immune function. We evaluated whether targeting APCs following injection with Poly I:C, LPS, flagellin, imiquimod and CpG-ODN would induce an antitumor response in the old. MATERIALS AND
methodsThe immune and antitumor responses induce Poly I:C, LPS, flagellin, imiquimod and CpG-ODN were compared in young (2 month old) and old (18 months) mice.
resultsOur results indicated that only intratumoral (i.t.) injections of CpG-ODN completely rejected the tumor in both young and old mice. Injections of Poly I:C also induced the rejection of tumors in the young but not in the old. Furthermore, i.t. injections of CpG-ODN promoted the development of protective memory responses in the young and the old. Analysis of the immune responses in the old indicated that CpG-ODN but not Poly-I:C induces: a pro-inflammatory Th1 type response; accumulation and activation of CD4+, CD8+ T and, NK cell responses; activation of APCs; and reduction in the number of Tregs. The activation of these immune-parameters positively correlates with the induction of an antitumor response.
conclusionsThese studies indicate that there are differences in the level of stimulation with TLR-ligands between young and old APCs and that the aged immune responses can be rescued and exploited for the induction of tumor immunity by targeting APCs with specific TLR-ligands. These results have important clinical implications for developing immunization strategies containing TLR-ligands that will be effective in both the young and old.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.